Clinical Trial Update: Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

View source ↗

Summary

Regulatory update noting that tucatinib in combination with capecitabine and trastuzumab has been approved for marketing in unresectable, previously treated HER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: HER2-positive Breast Cancer | Status: APPROVED_FOR_MARKETING